Share this article Share this article PALO ALTO, Calif., March 12, 2021 /PRNewswire/ HepaTx Corporation, Namocell Inc., and Takara Bio USA, Inc. (TBUSA) announced successful completion of the second phase of their collaboration on single cell analysis of hepatocyte-like cells (iHeps) differentiated from adipose tissue-derived stromal cells (ASCs) using Namocell s Single Cell Dispensers and Takara Bio s SMART-seq® kits to characterize HepaTx s novel cell therapies for liver disease. The results of the second phase demonstrated a 95% success rate in single cell isolation and library construction. Single cell RNA-seq showed distinct clusters of cells at various differentiation stages. The high reproducibility of results within sample groups will support development of novel cell therapies and validate production processes.